SSG
CTKB icon

Summit Securities Group’s Cytek Biosciences CTKB Stock Holding History

Summit Securities Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.45K Buy
+1,704
New +$8.04K ﹤0.01% 719
2025
Q3 		– Sell
-33,276
Closed -$113K – 1090
2025
Q2 		$113K Buy
+33,276
New +$111K 0.02% 345
2024
Q3 		– Sell
-878
Closed -$5K – 636
2024
Q2 		$5K Buy
+878
New +$5.27K ﹤0.01% 489

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Summit Securities Group's CTKB Position: Q1 2026 in Review

Summit Securities Group opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 1,704 shares worth $7.45K. The stake represents ﹤0.01% of the portfolio and ranks #719 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in CTKB as recently as Q2 2025.

Summit Securities Group first reported a position in CTKB in Q2 2024 and has held it in 3 quarters since. The position peaked at $113K in Q2 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Summit Securities Group held 1,704 shares of Cytek Biosciences worth $7.45K as of Q1 2026.
  • Cytek Biosciences was a new Summit Securities Group position in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #719 holding.
  • Summit Securities Group first reported a position in Cytek Biosciences in Q2 2024 and has held it in 3 quarters since.
  • Summit Securities Group's Cytek Biosciences position peaked at $113K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.